Proactive Investors USA & Canada | Fusion IP's Diurnal gets European boost for infant hydrocortisone treatment Proactive Investors USA & Canada Diurnal, one of Fusion IP's (LON:FIP) portfolio of university spin-off companies, has cleared a major regulatory hurdel in Europe for Infacort, its hydrocortisone treatment for children. The European Medicines Agency (EMA) has approved a Paediatric ... Beaufort Securities Breakfast Today including Fusion IP |
